Show simple item record

dc.contributor.authorYılmaz, T.
dc.contributor.authorAkman, M.
dc.contributor.authorTutluoğlu, Bülent
dc.contributor.authorAfrasyap, Lale
dc.contributor.authorGöylüsün, Veli
dc.contributor.authorÇelik, N.
dc.identifier.citationYilmaz, T., Akman, M., Tutluoğlu, B., Afrasyap, L., Göylüsün, V., ve Çelik, N. (1999). Plasma thrombomodulin levels in lung cancer patients. Panminerva medica, Edizioni Minerva Medica. 41(2), s.125-128 .en_US
dc.identifier.issn0031-0808 / 1827-1898
dc.description.abstractBACKGROUND: Thrombomodulin (TM) is a glycoprotein and besides its anticoagulant property it is accepted as an onco developmental antigen. Considering these properties we hypothesised that active TMB might have a role in cancer cell behaviour. METHODS: We measured serum TMB levels by the enzyme immunoassay method in 40 patients with lung cancer and 20 healthy subjects. RESULTS: TMB levels were found as 54.6 +/- 11.5 in controls and 60.9 +/- 31.2 ng/ml in lung cancer patients TM levels were 59.4 +/- 24.2 ng/ml in 24 epidermoid carcinoma patients, 65 +/- 50.2 ng/ml in 10 small cell carcinoma patients and 60 +/- 18.4 ng/ml in 6 adenocarcinoma patients. Patients with stage 4 and distant metastasis had a value of 65 +/- 33.9 ng/ml. No significant differences were found between healthy subjects and cancer patients. Also the differences between 3 groups of patients were insignificant. CONCLUSIONS: It was concluded that serum TMB levels could not be accepted as a tumour marker in lung cancer patients.en_US
dc.publisherEdizioni Minerva Medicaen_US
dc.titlePlasma thrombomodulin levels in lung cancer patientsen_US
dc.relation.journalPanminerva Medicaen_US
dc.contributor.departmentMaltepe Üniversitesi, Tıp Fakültesien_US
dc.relation.publicationcategoryUluslararası Editör Denetimli Dergide Makaleen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record